The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis by unknown
Mini-Review 
The Many Faces of Hepatocyte Growth Factor: 
from Hepatopoiesis to Hematopoiesis 
Reza Zarnegar and George K. Michalopoulos 
Department of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania 15261 
R 
ESEARCH performed over the past few years, in par- 
ticular,  has  made  it clear that,  in  addition  to the 
liver, hepatocyte growth factor (HGF)  1 affects vir- 
tually every tissue in the body ranging from the nervous 
system  to  the  immune  and  reticuloendothelial systems. 
Recent findings have also revealed that the biological re- 
sponses of target cells to HGF are not confined to the in- 
duction of cell proliferation and motility per se but include 
a plethora of effects such as inhibition of cell growth, in- 
duction of morphogenesis, stimulation of T  cell adhesion 
to  endothelium  and  migration,  enhancement  of neuron 
survival, and  regulation of erythroid differentiation. Fur- 
thermore, the discoveries of the HGF receptor as Met, of 
an HGF-related factor, called HGF-like protein, and  of 
HGF-like's receptor as Ron, a transmembrane tyrosine ki- 
nase similar to the HGF receptor, have added yet more 
levels of complexity to the  nature  of HGF and  its  now 
growing family. 
Structural Properties of HGF 
Hepatocyte growth factor is a mesenchymally derived hep- 
arin-binding glycoprotein that is secreted as a single-chain 
(pro-HGF), biologically inert precursor. Under appropri- 
ate conditions such as tissue damage (21), pro-HGF is con- 
verted to its bioactive form by proteolytic digestion at a 
specific site within the molecule. This proteolytic digestion 
may  be  mediated  by  urokinase  plasminogen  activator 
(uPA)  (27)  or by a  protease  homologous to factor XII 
(21). Mature HGF is a heterodimer, consisting of a 60,000 
Mr alpha and a 30,000 Mr beta chain held together by a sin- 
gle disulfide bond. The nucleotide sequences of human, 
rat, and mouse HGF cDNAs also predict that both chains 
of HGF are encoded by a  single open reading frame re- 
sulting in a 728-amino acid polypeptide. The alpha chain 
of HGF contains a hairpin loop (of ~27 amino acids) at its 
amino terminus and four unique domains known as kringles, 
while its beta chain contains a serine protease-like struc- 
ture (26). (For in depth review, see references 20 and 30.) 
The kringle motif, an 80-amino acid double-looped struc- 
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ture formed by three internal disulfide bridges, was first 
described for many of the enzymes involved in coagulation 
and fibrinolysis. Understandably, HGF resembles several 
coagulation/fibrinolytic related proteins such as plasmino- 
gen, but these proteins have no known growth potentiat- 
ing activity comparable to HGF. Conversely, HGF has no 
known protease activity, since the characteristic amino ac- 
ids  normally present  in  the  catalytic site  of serine pro- 
teases have been mutated in HGF, while the consensus se- 
quences which normally surround them still remain (26). 
These unique structural features of HGF have led to the 
assignment of HGF as the prototype of a  new family of 
growth factors. 
The HGF Receptor 
Recent studies have shown that HGF transduces its multi- 
ple  biological  effects  such  as  mitogenesis,  motogenesis, 
metastogenesis and morphogenesis via activation of a trans- 
membrane tyrosine kinase cell surface receptor known as 
Met  (2,  40).  The met protooncogene was  cloned and se- 
quenced before HGF itself had been cloned and was ini- 
tially discovered as an activated oncogene based on its abil- 
ity to transform normal fibroblast cell lines (4). The mature 
Met receptor is  a  heterodimer held together by disulfide 
bonds and consists of an alpha chain that is ~50,000 Da 
which remains entirely extracellular, and a large polypep- 
tide chain with a molecular mass of 145,000 (named the beta 
chain) which traverses the plasma membrane and contains 
the intracellular tyrosine kinase domain. Both polypeptide 
chains of the Met receptor are derived posttranslationally 
from a single chain precursor by proteolytic cleavage at a 
specific site within the precursor molecule. (For review see 
reference 9).  The HGF receptor (HGFR) is expressed in 
normal epithelium of almost every tissue; however, other 
cell types such as melanocytes, endothelial ceils, microglial 
cells,  neurons, hematopoietic cells,  and a variety of tumor 
cell lines of various origins also express this receptor. 
HGF, the Hepatocyte and Liver Regeneration 
HGF's existence was originally postulated based on stud- 
ies in which liver regeneration was surgically stimulated by 
removal of two-thirds of the liver in rats resulting in the 
appearance  of  a  hepatocyte mitogen  in  the  peripheral 
blood. Following two-thirds partial hepatectomy, plasma 
HGF levels are  found to be  15-  to 25-fold greater than 
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curs sharply after acute liver injury after administration of 
chemicals such as carbon tetrachloride. The levels of HGF 
then decline within 24 h but remain elevated for the dura- 
tion of the regenerative response. Analogous changes in 
plasma HGF levels have also been described after admin- 
istration of chemicals to rats that augment liver DNA syn- 
thesis and liver weight (19), such as phenobarbital, dilan- 
tin, valium, and others that, in long term administration, 
function as  liver tumor promoters, as well as  in human 
liver disease whenever a massive loss of hepatocytes oc- 
curs such as in a condition known as acute fulminant hepa- 
titis (37). These findings, as well as several other direct and 
indirect pieces of evidence, implicate HGF as an important 
paracrine and perhaps endocrine regulator of liver growth. 
(For review see reference 20). 
The HGF/HGFR system may also influence other as- 
pects of liver growth and development. In addition to its 
ability  to  stimulate  proliferation  and  morphogenesis  of 
mature hepatocytes, HGF is linked to hepatocyte stem cell 
proliferation and differentiation (8). As stem cells in the 
liver proliferate, nearby Ito cells also undergo cell division. 
These neighboring cells express HGF pointing to a possi- 
ble paracrine effect of HGF on the growth of stem cells 
which  express HGFR  (8).  Several studies  also  strongly 
suggest a role for HGF in liver embryogenesis. In situ hy- 
ridization studies reveal that HGF and HGFR expression 
is highest in the liver as compared to other tissues (Katyal 
and Michalopoulos, unpublished observations). Addition- 
ally, HGF protein is also present in the developing liver, 
especially in the hematopoietic cells (5), which may impli- 
cate HGF not only in liver formation but also in hemato- 
poiesis  (see below).  Other supportive  evidence includes 
the finding that HGF may be involved in the transforma- 
tion of apolar  embryonic hepatocytes into  acinar  struc- 
tures prior to the  appearance  of the  mature  hepatocyte 
plate (34) which are the same morphological changes seen 
during liver regeneration and in hepatocytes cultured in 
type I  collagen gels in the presence of HGF. Direct evi- 
dence on the role of HGF in liver growth and develop- 
ment comes from very recent investigations on transgenic 
mice homozygous for a  null mutation in the I-IGF gene 
(knock-out mice). These studies have revealed that such 
animals do not survive beyond day 15 of embryonic devel- 
opment with most notable defects seen in liver formation 
and architecture primarily due to an extensive loss of he- 
patic parenchyma (31). Moreover, lack of HGF expression 
also affected the development of the placenta as was evi- 
denced by a  severe reduction in the number of tropho- 
blasts (31, 38). 
Other  investigations have defined a  fundamental role 
for HGF in mediating responses to tissue injury in other 
organs in adults. In animal models in which kidney (16) or 
lung (42) has been damaged experimentally, HGF expres- 
sion is induced markedly. This increase in HGF mRNA is 
followed by increases in the level of pro-HGF and in its 
subsequent activation by proteolytic cleavage to the bioac- 
tive heterodimeric form in the damaged tissue (21). Addi- 
tionally, when exogenous HGF is  administered to these 
animals, it remarkably enhances the regeneration of the 
injured organ (20). These findings indicate that HGF is ac- 
tivated locally which may in part explain the lack of re- 
sponse to the biological effects of HGF in uninjured tis- 
sues. The discovery that the mRNAs for HGF (20) and the 
HGF receptor (23) are induced in stromal and epithelial 
cells, respectively, by inflammatory cytokines such as IL-1, 
IL-6, and TNFa also supports the idea that this ligand/re- 
ceptor system is involved in mediating inflammatory re- 
sponses to tissue injury. These studies have defined HGF 
as a major mediator of tissue repair and organ regeneration 
and underscores its potential use as a therapeutic agent for 
treating diseases such as acute liver or renal failure. 
Biological Effects of HGF on Other Cell Types 
The  growth  regulating  effects  of HGF  on  various  cell 
types, other than  hepatocytes, is  now well-documented. 
(For review see references 20 and 30). One of the hallmark 
in vitro responses to HGF is the induction of cell motility 
and dissociation (scattering) of various normal and malig- 
nant epithelial cells. Based on this property, HGF was in- 
dependently purified and characterized from the culture 
medium of fibroblast cell lines such as MRC-5,  and was 
named scatter factor (35). Subsequent investigations, how- 
ever, revealed that this molecule is identical to HGF (39). 
A  third type of biological activity associated with HGF is 
its remarkable morphogenic effects on epithelial tissues. 
HGF is now believed to be most potent epithelial morpho- 
gen inducing formation of branching tubules and gland- 
like structures in epithelial cells derived from kidney or 
mammary tissue in vitro (24, 33). 
Based on these properties, it has been postulated that 
HGF is a mediator of epithelial-mesenchymal interaction 
and interconversion. (For a review see reference 29). Most 
tissues either express HGF mRNA or contain HGF pro- 
tein. Among these are blood (megakaryocytes, monocytes, 
leukocytes, and platelets), brain, bone marrow, liver, lung, 
kidney, placenta, spleen,  and skin. The highest levels of 
HGF mRNA are detected in the adult lung, liver, skin, and 
spleen  although  the  other tissues  mentioned all  contain 
detectable levels of HGF mRNA and/or protein. In gen- 
eral, HGF mRNA is expressed in stromal cells such as fi- 
broblasts, smooth muscle cells, mast  cells, macrophages, 
endothelial cells, leukocytes, and megakaryocytes of vari- 
ous tissues but not in epithelial cells. HGF receptor ex- 
pression, on the other hand, is mainly detected in epithe- 
lial cells. This unique expression pattern in combination 
with the mitogenic, motogenic, and morphogenic proper- 
ties of HGF support the idea that this ligand is an impor- 
tant paracrine mediator of the interaction between the ep- 
ithelial  and  stromal  compartments  of  various  tissues 
during development and in the maintenance of homeosta- 
sis in adult tissues (29, 32). 
HGF has also been shown to induce mesenchymal to ep- 
ithelial conversion in fibroblasts overexpressing HGF and 
HGFR when these cells are injected into nude mice (36). 
In another investigation using cell lines derived from meta- 
naphric ridge cells of mouse embryos, it was shown that 
HGF stimulates epithelial differentiation of these mesen- 
chymal cells suggesting that this cytokine may be involved 
in the early commitment of cells in the kidney (15). The re- 
cent findings by Woolf et al. (41) show that simultaneous 
expression of HGF and HGFR occurs in the kidney mes- 
enchyme during the early development of the mouse kid- 
ney and that anti-HGF antibody inhibits the differentia- 
tion of metanephric mesenchymal cells into the epithelial 
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metanephric organ cultures. Other studies have also impli- 
cated HGF in early embryological processes such as the 
formation of the primitive streak and induction of neural 
tissues as demonstrated by studying HGF and HGFR ex- 
pression in Xenopus and chick during early stages of de- 
velopment and by ectopic application of HGF in a chick 
embryo model. (For review see reference 20.) 
The  potential  participation  of HGF in  organogenesis 
and the later stages  of embryonic development has also 
been well documented by studying HGF and HGFR ex- 
pression in rodents (5, 32). As stated, recent studies have 
shown that the disruption of the HGF gene results in em- 
bryonic lethality, primarily due to defects in proper devel- 
opment of the placenta and liver (31, 38). In these studies, 
however, other organs and tissues where HGF and HGFR 
are reportedly expressed during embryogenesis (such as 
lung, kidney, and the central nervous system), appeared 
normal at the time of death (day 15 of gestation). This may 
indicate  that  either  HGF  is  not  essential  for the  early 
stages of embryogenesis or that compensation or redun- 
dancy exists in the HGF signaling network. It should be 
noted that further analysis of these animals has been ham- 
pered due to their death in utero preventing additional in- 
vestigations on the functions of HGF in other processes 
such as terminal differentiation and maturation or regen- 
eration of other tissues (31). 
It should be emphasized that  although  epithelial cells 
are one of the major targets of HGF, as more investiga- 
tions are conducted, it is becoming clear that nonepithelial 
cell types such  as  hematopoietic, lymphoid, neural,  and 
skeletal muscle cells also respond to the multifaceted ac- 
tions of HGF. The first clue indicating that HGF may be 
involved in hematopoiesis came from studies on progeni- 
tor-enriched murine bone marrow cells and on several mu- 
fine myeloid progenitor tumor cell lines blocked in  the 
early stages of myeloid differentiation. Such investigations 
revealed, first, that these cells express the HGFR, and sec- 
ond, that HGF synergizes with IL-3 or GM-CSF to sup- 
port the growth of these cells in culture (17, 22). Conflict- 
ing  results,  however,  were  obtained  by  these  two 
investigations with regard to whether HGF alone stimu- 
lates  mitogenesis  in  myeloid  progenitor  cell  lines.  Al- 
though  HGF synergized with  other factors to  stimulate 
growth of progenitor cells, it apparently did not influence 
the  pattern of myeloid differentiation since the ratio of 
macrophages  to  granulocytes  in  resultant  colonies  re- 
mained similar to those obtained with IL-3 or GM-CSF 
alone (17). 
Galimi et al. (10) recently reported that the HGF recep- 
tor is present in  a  small  fraction of highly-enriched he- 
matopoietic progenitor cells  from human  bone  marrow 
and peripheral blood and showed that, in the presence of 
erythropoietin, HGF  induces  the  formation  of colonies 
along the erythroid lineage when cultured in vitro. How- 
ever, in the presence of erythropoietin and stem cell fac- 
tor, it was demonstrated that HGF supports the growth of 
multipotent  colonies  (granulocyte-erythroid-megakary6- 
cyte) rather than recruiting erythroid precursors. 
The differences in  the  results  of the  experiments de- 
scribed above may be due to variations in technique such 
as culture conditions (i.e., presence or absence of particu- 
lar cytokines and doses), purity of cells, or simply because 
so few studies have addressed HGF's involvement in he- 
matopoiesis. Additionally, whether HGF's mitogenic/dif- 
ferentiation effects on hematopoietic stem cells are medi- 
ated through the HGFR directly or whether HGF through 
its receptor causes secretion of other modulating cytokines 
has not been addressed in studies thus far completed. Re- 
gardless of how HGF elicits such responses, the fact that 
hematopoiesis is altered at all in the presence of HGF de- 
serves further study. 
The role of the HGF family in hematopoiesis and reticu- 
loendothelial cell function is further underscored by other 
findings.  It has been shown  that the HGF-like receptor 
(Ron) is highly expressed in hematopoietic stem cells (12) 
and  monocytes (11).  Moreover, HGF-like protein  (also 
known  as macrophage  stimulating  protein) was  demon- 
strated to elicit monocyte migration through Ron activa- 
tion (11). Biological activities affecting reticuloendothelial 
cells have also been described for HGF and the HGFR us- 
ing in vitro models. These include activation of the oxida- 
tive response of human neutrophils (13), promotion of ad- 
hesion and migration of a subset of human T cells (1), and 
enhancement of humoral immune responses in murine B 
cells (6). 
Recently, in vivo studies in which HGF was implanted 
into rabbits have demonstrated that HGF has angiogenic 
activities (3). Interestingly, HGF has also been linked to 
Kaposi's  sarcoma  (KS),  a  form  of human  neoplasm  in 
which the cellular origin has not been defined, but is be- 
lieved to be an endothelial derivative. Several lines of evi- 
dence support this possibility. First, HGF is secreted by 
HTLV-II-infected T lymphocytes; secondly, HGF induces 
endothelial cells to convert to  a  Kaposi  sarcoma tumor 
cell-like phenotype; thirdly, antibody against HGF inhibits 
the  growth  of  KS  cells  in  culture;  and  lastly,  HGF  is 
present in KS lesions (25). 
The presence of HGF and its receptor in specific regions 
of the  developing and adult mammalian nervous system 
points  to  the  fact  that  this  ligand/receptor system  may 
have  a  neurotrophic function  (14).  Recently, HGF was 
shown to promote the survival of motor neurons and en- 
hance  the  neurotrophic function of ciliary neurotrophic 
factor. In other studies, Krasnoselsky and colleagues re- 
ported  that  rat  sciatic  nerve  Schwann  cells  express the 
HGF receptor and strongly respond to the mitogenic ef- 
fects of HGF in culture (18). 
HGF has also been examined in the context of endo- 
crine function. Studies on the effects of HGF on the endo- 
crine system show that HGF may contribute to the forma- 
tion  and  maintenance  of  organs  involved  in  hormone 
secretion such as the pancreas and the thyroid. Using pri- 
mary organ cultures of human fetal pancreas, Otonkoski 
et al. have recently reported that HGF is the most potent 
inducer of ~-cell proliferation and formation of islet-like 
cell clusters subsequently resulting in insulin production in 
vitro (28). HGF also seems to regulate the growth and func- 
tion of the thyroid gland as revealed by in vitro studies (7). 
Although the early work on HGF was confined almost 
exclusively to one organ, the liver, researchers with wide- 
ranging scientific interests have helped over the years to 
define the multifaceted functions and target cells of HGF. 
Clearly, however, much remains to be learned about HGF, 
and more biological and physiological roles for this growth 
factor will undoubtedly be revealed. 
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